SION.US Sionna Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
3.07 USD
Close of Nov 18, 2026
2.99 54.97
Market cap
USD 139M
P/E
-
P/B
0.59x
ROE
-49.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SION.US undervalued?

Graham number

The Graham number of Sionna Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sionna Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Sionna Therapeutics, Inc. Common Stock yet.

Sionna Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sionna Therapeutics, Inc. Common Stock

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 tria…

Full company profile